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Abstract
Objective To encourage the development of drugs for rare
diseases, orphan drug legislation has been introduced in the
USA (1983) and in the EU (2000). Recent literature
discusses factors that may influence the development of
new orphan medicinal products in the EU. This study aims
to identify predictors for successful marketing authorisation
of potential orphan drugs in the EU.
Methods A comparison between randomly selected author-
ised and a matched sample of not-yet-authorised orphan
drug designations has been performed. Determinants in the
study included characteristics of the indication, of the product
and of the sponsor. Data were collected from the public
domain only.
Results Orphan drug approval was strongly associated with
previous experience of the sponsor in obtaining approval
for another orphan drug (OR=17.3, 95% CI=5.6–53.1).
Furthermore, existing synthetic entities compared to bio-
technology products tended to have a higher likelihood of
reaching approval status (OR=3.9, 95% CI=0.9–16.6).
Conclusion This study showed that experience of a
company in developing orphan drugs is an important
predictor for subsequent authorisation of other orphan
drugs. The same applies for existing (synthetic) molecules,
for which much knowledge is available. Further research
should be directed towards studying the quality of the
clinical development program of those designated orphan
medicinal products not reaching approval status.
Keywords Orphan drugs . Rare diseases .
Drug development . Regulatory affairs
Introduction
In Europe and the United States (USA) together, more than 55
million people suffer from a rare disease. It is estimated that
approximately 5,000 to 7,000 rare diseases exist, and every
year about 250 new ones are described [1, 2]. This is partly
due to our continuously improving knowledge on disease
biology and genomics, which allows more prevalent diseases
to be broken down into several rare diseases. In addition to
this, new symptoms, mechanisms and aetiologies are
described in literature, representing more new diseases [3,
4]. As yet, for many rare diseases, no treatment is available
[2, 5]. The high costs and risks of drug development,
combined with difficulties in conducting clinical trials in
small patient populations and the small market size,
discourage the pharmaceutical industry from developing
drugs for these rare diseases [2, 6]. Finding ways to bring
drugs for rare diseases to patients is therefore an important
public health issue [1, 7].
Consequently, several jurisdictions have put forward
incentives to stimulate the development of drugs for rare
diseases. Following the successful Orphan Drug Act in the
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USA, the European Union (EU) introduced its Regulation
on Orphan Medicinal Products in April 2000 [8–10]. The
systems have much in common, although a few differences
exist. In the USA, drugs indicated for a maximum of
200,000 patients (equivalent to 7 patients per 10,000
residents) are eligible for orphan drug designation. In the
EU, an orphan designation will only be provided by the
European Commission if the product is intended for the diag-
nosis, prevention or treatment of a life-threatening or
chronically debilitating condition that affects fewer than 5 in
10,000 patients. Moreover, the sponsor should establish that
there exists no satisfactory method for the diagnosis, treatment
or prevention of this condition, or if such exists, that the new
product will be of significant benefit for those affected by that
condition [3, 10–12].
Designated potential orphan drugs in the EU are entitled
to several incentives, of which a market exclusivity of
10 years upon authorisation is the most important one [12].
Other incentives are direct access to the centralised
procedure for European marketing authorisation, 50% fee
reductions for regulatory procedures and free scientific
advice during the development process [13]. With this
designation procedure, the EU aims to stimulate bottom-up
initiatives to further develop possible orphan drugs.
Thus, an orphan drug designation system creates a ‘pre-
screen’ of promising future orphan drugs. However, to be
designated does not automatically mean an orphan drug will
be authorised for marketing. A recent study by Joppi pointed
out that in April 2004, only 7.1% of the EU designated
potential orphan drugs were approved for marketing, ques-
tioning whether the incentives are sufficient to provide the
European market with new orphan drugs [14]. These
observations give strong impetus to the question of what
determines successful development and marketing author-
isation of an orphan drug. In other words: what makes an
orphan designation result in an authorisation? A paper by
Dear argued that the US Orphan Drug Act is so successful
because of tax grants, which are not available in Europe [12].
Other factors that have been suggested as relevant in terms of
influencing the likelihood of approval are the potential of the
sponsor to carry out suitable clinical trials and the level of
patient involvement in the development process [5]. How-
ever, beyond these suggested factors, additional character-
istics may be of importance that have not been studied yet.
Since all products have to comply with the criteria of
quality, safety and efficacy, we hypothesise that designated
orphan medicinal products that have not (or not yet)
obtained marketing approval therefore either have unfav-
ourable characteristics or the sponsor of the product has not
been able to show the favourability of the product
characteristics. The latter can have multiple causes, includ-
ing lack of experience or insufficient means for the clinical
development program. In addition to this, the type of
indication may influence the perspectives on marketing
authorisation, as the risk-benefit balance may be influenced
by the degree of severity of specific disease classes. The
objective of this study is therefore to identify predictors of
successful marketing authorisation in the EU.
Methods
Selection of candidate orphan medicinal products
The cohort of 386 designated orphan drugs and orphan
drug candidates has been followed from the start of the EU
Regulation on Orphan Medicinal Products in April 2000.
We enrolled all designated orphan medicinal products with a
marketing authorisation by the European Commission up to 1
October 2006 in our analysis and compared these to a subset
of the designated, but not yet authorised, orphan drugs. To
avoid potential bias due to time-related differences in the
probability of getting authorisation, for each authorised
product, a random sample of up to two designated products
from the same time period (120 days before to 120 days after)
as the designation date of the authorised product was selected.
Authorised orphan drugs with multiple authorised indications
(imatinib, sunitinib and dasatinib) were sampled to up to two
unapproved orphan drugs for each indication.
Data collection
To test our hypothesis, we collected data for each product
on the indication, the product and the sponsor. Selection of
data was limited to the public domain. Indication character-
istics included data on the type of disease and disease
prevalence for which the product is indicated. Product
characteristics included data on the type of product,
proposed route of administration and previous approval or
designation of the molecule in other geographic regions than
the EU. Sponsor characteristics included those details of the
sponsor that may be indicative for demonstrating the favour-
ability of the product, including the size of the company,
geographic region of drug development and experience of the
company with drug development. A full list of these variables
is shown in Table 1. If available, EMEA definitions were
used for the classification of the subcategories and variables.
Sources included the EMEA website (http://www.emea.
europa.eu), European Public Assessment Reports (EPARs),
sponsor websites, annual reports, press releases, and peer-
reviewed scientific literature.
Data analysis
Characteristics of approved and unapproved orphan medic-
inal products were compared using a univariate analysis.
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Odds ratios (OR) and 95% confidence intervals (CI) were
calculated for each characteristic in the three categories.
The outcome was defined as a successful EU marketing
authorisation within the study period (April 2000-October
2006). To test whether any of the characteristics were
mutually related, a multivariate model was used in which
the characteristics with statistically significant crude ORs
were compared using a backwards selection procedure.
Results
From the start of the EU Regulation on Orphan Medicinal
Products (April 2000) up to 1 October 2006, 31 orphan
medicinal products obtained marketing authorisation. One
product (imatinib) has been authorised for four indications,
and two other products (sunitinib and dasatinib) have been
authorised for two indications, resulting in 36 approved
orphan indications. A total of 60 designated (unauthorised)
products were sampled to serve as controls. A small,
statistically significant difference in the stage of develop-
ment between the two groups was found for those products
for which clinical trials were initiated, but not yet
completed (P=0.02), while this was not the case for
products for which experimental model studies had been
initiated or completed (P=0.08), and for products for which
at least one clinical trial was completed (P=0.22).
Of the 31 authorised drug products, the majority (58.3%)
were designated in the first 2 years of the EU Regulation on
Orphan Medicinal Products (2000–2001). Twelve were ap-
proved under exceptional circumstances, and one (sunitinib)
had obtained conditional approval. Seven (22.6%) had received
some form of protocol assistance or scientific advice from the
EMEA. Of the 60 unauthorised designations, at least 43
(71.7%) were still in development in October 2006; of these,
one had filed for market authorisation and another one had been
authorised by November 2006. The development of six
products could be classified as halted or on hold. For 11
products, recent data on the development status were not
available.
Table 2 shows an overview of the clinical characteristics
of all 31 authorised orphan drugs for 36 indications, stratified
by indication category and prevalence group of the indica-
tion. Disease categories are based on ATC classes or
combinations thereof that are also used by the Commission
for Orphan Medicinal Products (COMP) of the EMEA [15].
The majority of the products were intended for oncologic
and immunomodulatory diseases (ATC class L) (16, 44.4%)
or alimentary and metabolic diseases (ATC class A) (9,
25.0%). In addition, most (24, 66.7%) authorised drugs
were intended for diseases with a prevalence lower than 1
in 10,000. Of the 16 approved oncology drugs, 13 (81%)
were developed by large companies, 7 (44%) originated
from the USA and 5 (31%) from Switzerland. All these
products were based on synthetic entities, and the majority,
12 (75%), were intended for oral use, whereas 4 (25%)
were intended for systemic use.






Antineoplastic and immunomodulating (L)
Cardiovascular, blood and respiratory
(C, B, R)
Anti-infectives (J)
Alimentary tract and metabolism (A)






Inheritable Majority of cases caused by genetic
inheritance
Chronic disease Disease duration is generally over 3 months
Childhood disease Majority of diagnoses before age 18
Product characteristics
Type of molecule Biotechnological (EMEA list A, including
gene therapy)
Innovative synthetic entities (EMEA list B),









Product had orphan designation for this
indication elsewhere before EMEA orphan
designation
Previously authorised Product was approved for this indication
elsewhere before EMEA orphan designation
Sponsor characteristics
Type of company Large (>250 employees or 50M turnover)
Medium (50–249 employees or 10–50M
turnover)








Sponsor has marketing authorisation for
other medicinal products as of 1 Oct 2006
(anywhere in the world)
Other ODs designated Sponsor has other designated orphan
medicinal products as of 1 Oct 2006
(anywhere in the world)
Other ODs authorised Sponsor has other authorised orphan
medicinal products as of 1 Oct 2006
(anywhere in the world)
ATC Anatomical Therapeutic Chemical, NCE new chemical entity,
OD orphan drug
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The results of the univariate comparison between author-
ised and not-yet-authorised orphan drugs are shown in Table 3.
For the categories of product characteristics and sponsor
characteristics, a statistically significant association was
observed for all the determinants except for the continent
of drug development and for products with a previous
orphan designation outside the EU. The association was
strongest for those characteristics that were related to the
experience of the sponsor with drug development. Previous
authorisation of an orphan drug by the sponsor was
associated with a 16-fold increase in the chance of author-
isation compared to no previous authorisation (OR=16.2,
95% CI=5.5–47.4), whereas previous authorisation of other
drugs and previous designation of another potential orphan
Table 2 Summary of characteristics of authorised orphan medicinal products from April 2000 to October 2006 [21]
EU orphan
designation number
INN name Designated orphan indication Disease
group
Prevalence
EU/3/00/002 Agalsidase alpha Treatment of Fabry disease A <1/10,000
EU/3/00/003 Agalsidase beta Treatment of Fabry disease A <1/10,000
EU/3/00/006 Miglustat Treatment of Gaucher disease A <1/10,000
EU/3/00/007 Carglumic acid Treatment of N-acetylglutamate synthetase (NAGS) deficiency A <1/10,000
EU/3/00/008 Arsenic trioxide Treatment of acute promyelocytic leukaemia L <1/10,000
EU/3/00/010 Anagrelide
hydrochloride
Treatment of essential thrombocythaemia L 1–3/10,000
EU/3/00/011 Busulfan Conditioning treatment prior to hematopoietic progenitor cell
transplantation
L <1/10,000
EU/3/00/012 Nitisinone Treatment of tyrosinaemia type I A <1/10,000
EU/3/00/014 Iloprost Treatment of primary and several secondary forms of pulmonary
hypertension
C, B, R 1–3/10,000
EU/3/00/018 Alglucosidase
alpha
Treatment of glycogen storage disease type II (Pompe’s disease) A <1/10,000
EU/3/01/019 Bosentan Treatment of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension
C, B, R <1/10,000
EU/3/01/020 Ibuprofen Treatment of patent ductus arteriosus C, B, R 1–3/10,000
EU/3/01/021 Imatinib mesilate Treatment of chronic myeloid leukaemia L <1/10,000
EU/3/01/022 Laronidase Treatment of mucopolysaccharidosis, type I A <1/10,000
EU/3/01/023 Pegvisomant Treatment of acromegaly H <1/10,000
EU/3/01/025 Galsulfase Treatment of mucopolysaccharidosis, type VI (Maroteaux-Lamy
syndrome)
A <1/10,000
EU/3/01/048 Ziconitide acetate Treatment of chronic pain requiring intraspinal analgesia M, N 1–3/10,000
EU/3/01/050 Zinc acetate
dihydrate
Treatment of Wilson’s disease A <1/10,000
EU/3/01/055 Cladribine Treatment of hairy cell leukaemia L 3–5/10,000
EU/3/01/059 Dexrazoxane Treatment of anthracycline extravasations Other <1/10,000
EU/3/01/061 Imatinib mesilate Treatment of gastrointestinal stromal tumours (GIST) L <1/10,000
EU/3/01/070 Celecoxib Treatment of familial adenomatous polyposis L <1/10,000
EU/3/01/082 Clofarabine Treatment of acute lymphoblastic leukaemia L <1/10,000
EU/3/02/086 Porfimer sodium Treatment of high-grade dysplasia in Barrett’s oesophagus Other 1–3/10,000
EU/3/02/092 Deferasirox Treatment of chronic iron overload requiring chelation therapy Other 1–3/10,000
EU/3/02/102 Mitotane Treatment of adrenal cortical carcinoma L <1/10,000
EU/3/02/131 Sodium oxybate Treatment of narcolepsy M, N 3–5/10,000
EU/3/03/178 Sildenafil Treatment of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension
C, B, R <1/10,000
EU/3/04/234 Sitaxentan Treatment of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension
C, B, R 1–3/10,000
EU/3/05/267 Sunitinib Treatment of malignant gastrointestinal stromal tumours L <1/10,000
EU/3/05/268 Sunitinib Treatment of renal cell carcinoma L 3–5/10,000
EU/3/05/304 Imatinib mesilate Treatment of acute lymphoblastic leukaemia L <1/10,000
EU/3/05/305 Imatinib mesilate Treatment of dermatofibrosarcoma protuberans L 1–3/10,000
EU/3/05/338 Dasatinib Treatment of acute lymphoblastic leukaemia L <1/10,000
EU/3/05/339 Dasatinib Treatment of chronic myeloid leukaemia L <1/10,000
EU/3/06/364 Sorafenib Treatment of hepatocellular carcinoma L 3–5/10,000
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drug by the sponsor yielded odds ratios (95% CI) of 11.5
(3.2–42.2) and 8.0 (2.5–25.7) respectively. Furthermore,
previous authorisation outside the EU was also associated
with higher chances for authorisation in the EU (OR=4.0,
95% CI=1.1–14.5). Finally, the type of product is partly
associated with market authorisation. Although the associa-
tion for innovative synthetic entities [e.g. new chemical
entities (NCEs)] such as imatinib was not statistically
significant compared to biotechnology products (OR=2.0,
95% CI=0.7–6.1), existing synthetic entities, such as arsenic
trioxide and busulfan, were associated with higher chances
of market authorisation (OR=3.3, 95% CI=1.1–10.6).
The results from the multivariate model, which assessed
whether any of the statistically significant characteristics
Table 3 Results for the comparison between authorised and not-yet-authorised orphan medicinal products













respiratory (C, B, R)
5 7 1.4 (0.4–5.2)
Anti-infectives (J) 0 4 NA
Alimentary tract and metabolism (A) 9 5 3.6 (1.0–12.4)
Musculoskeletal and nervous (M, N) 2 7 0.6 (0.1–3.0)
Hormones (H) 1 1 2.0 (0.1–34.0)
Various (V) 2 2 2.0 (0.3–15.5)
Prevalence group <1/10,000 24 26 1
1–3/10,000 8 22 0.4 (0.2–1.0)
>3/10,000 4 6 0.7 (0.2–2.9)
Inheritable No 25 44 1
Yes 11 16 1.2 (0.5–3.0)
Chronic disease No 4 13 1
Yes 32 47 2.2 (0.7–7.4)
Childhood disease No 31 45 1
Yes 5 15 0.5 (0.2–1.5)
Product characteristics
Type of molecule Biotechnology 6 20 1
Innovative synthetic 15 25 2.0 (0.7–6.1)
Existing synthetic 15 15 3.3 (1.1–10.6)
Pharmaceutical formulation Parenteral 13 30 1
Oral 21 12 4.0 (1.5–10.6)
Other 1 14 0.2 (0.0–1.4)
Previously designated No 19 41 1
Yes 16 17 2.0 (0.9–4.9)
Previously authorised No 27 54 1
Yes 8 4 4.0 (1.1–14.5)
Sponsor characteristics
Type of company Large 27 24 1
Medium 7 18 0.4 (0.1–1.0)
Small and institutions 2 16 0.1 (0.0–0.5)
Continent of drug development North America 16 22 1
Europe 20 34 0.8 (0.4–1.9)
Asia 0 3 NA
Other medicinal products
authorised
No 3 29 1
Yes 31 26 11.5 (3.2–42.2)
Other ODs designated No 4 30 1
Yes 30 28 8.0 (2.5–25.7)
Other ODs authorised No 6 45 1
Yes 28 13 16.2 (5.5–47.4)
OR Odds ratio, 95% CI 95% confidence interval, ATC Anatomical Therapeutic Chemical, NA not applicable, OD orphan drug
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were related, are shown in Table 4. This model yielded two
independent predictors of successful marketing authorisa-
tion, namely the experience of the sponsor having other
orphan medicinal products authorised and the type of
product. The association was strongest for the authorisation
of other orphan products by a sponsor (OR=17.3, 95% CI=
5.6–53.1). Moreover, we found a tendency toward an
association for the type of product, with an OR (95% CI)
of 3.9 (0.9–16.6) for existing synthetic entities compared to
biotechnology products, while no association was observed
for innovative synthetic entities compared to biotechnology
products (OR=1.9, 95% CI=0.5–7.7).
Discussion
This study reveals two independent characteristics of an
orphan medicinal product that are associated with market-
ing authorisation: the experience of a company in develop-
ing drug products and the type of drug product in
development.
First, we showed that experience of a company in
obtaining authorisation for orphan drugs was identified as
the most important predictor of market authorisation.
Companies that have successfully brought an orphan drug
to the market increase their odds of obtaining market
authorisation for consecutive orphan drugs more than 17-
fold. These results are in line with opinions expressed by
many experts, however they are now supported by real data
and emphasise the importance of an experienced partner in
bringing a product to the market for small and medium-
sized enterprises (SMEs) whose experience is often limited
[5]. This observation is verified by the fact that many
former SMEs with one or more approved orphan drugs
have acquired the necessary experience by bringing on
board experienced management at an early stage.
The EMEA has addressed this issue by offering protocol
assistance and scientific advice to sponsors of designated
orphan drugs. Another important recent incentive to
overcome this hurdle is EMEA’s dedicated SME office,
which addresses the regulatory needs of SMEs [16]. These
incentives seem to be good steps forward to guide smaller
and relatively inexperienced companies through the regu-
latory maze in the development process. Although 80
procedures for protocol assistance had been completed by
April 2005 [15], we found that only 4 of the products that
were approved in that period had obtained scientific advice
or protocol assistance from the EMEA. Furthermore, of the
31 products authorised by October 2006, only 7 (22.6%)
received protocol assistance or scientific advice. In contrast,
28 (77.8%) of the 36 approved orphan indications were
developed by a company that had successfully brought
another orphan drug to the market in Europe or the USA.
The development of imatinib is a good example of this. It
was developed by a large company with extensive
experience in developing and marketing medicinal products
[17].
The other independent predictor that was identified
was the type of product. Although not significant, it shows
that the odds of authorisation for products based on existing
synthetic entities may be about four times higher compared
to biotechnological products. Only 6 of the 31 orphan drugs
approved in the EU up to October 2006 were of
biotechnological origin; of these, 5 are used for enzyme
replacement therapy for metabolic disorders. This finding is
not unexpected, as the development of existing synthetic
entities into drug products is generally considered much
more straightforward than the development of a biotech
product. This group also includes orphan drugs based on
existing approved therapies, such as celecoxib and sildena-
fil, for which development was only a matter of an
indication extension. This can be one of the reasons why
the relatively young European Regulation on OMPs has
yielded such a high share of orphan drugs based on existing
synthetic entities.
In contrast to the EU, half of the biotechnological
products approved in the USA in the period 1982–2002
were designated orphan drugs [3]. The US Orphan Drug
Act is therefore frequently mentioned as one of the key
factors that has stimulated the US biotech industry in its
growth. Several of the world’s largest, US-based biotech
companies have in common that their first approved
product was an orphan drug [3, 18]. This is illustrated by
the fact that of the six approved biotech OMPs in the EU,
five were originally developed in the USA. Since the US
Orphan Drug Act was initiated nearly 25 years ago, those
companies have grown from SMEs to multinational
companies and have since acquired much more experience
in drug development than the current European biotech
companies with orphan drug designations in their portfolio.
On the other hand, the small number of European biotech
orphan drugs is compensated for by the relatively large
Table 4 Multivariate analysis of predictors of marketing authorisation
of orphan medicinal products in Europe
Predictor Value ORa (95% CI)
Other ODs approved No 1.0
Yes 17.3 (5.6–53.1)
Type of product Biotechnology 1.0
Innovative synthetic entity 1.9 (0.50–7.7)
Existing synthetic entity 3.9 (0.9–16.6)
OR Odds ratio, 95% CI 95% confidence interval, OD orphan drug
a Adjusted for significant variables in the univariate analysis (includ-
ing other ODs approved and type of product), followed by a
backwards elimination procedure. Predictors in the table are those that
remained in the multivariate analysis
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number of orphan products based on existing synthetic
molecules. Examples of these are the products from the
French SME Orphan Europe, which are all based on
existing molecules. This underlines that experience of a
company is even more important for the relatively more
complex biotechnological products. Since much clinical
experience is already available, especially for existing
synthetic molecules, this emphasises that, next to the
experience of a company, experience with a drug product
is also important.
Except for products indicated for alimentary tract and
metabolism-related diseases (ATC class A), none of the
characteristics related to the type of the indication showed a
statistically significant association with market authorisa-
tion. This finding matched with our hypothesis that only the
characteristics of the drug product itself or the development
program of the sponsor determines the chances for market
authorisation. An interesting observation here is that the
number and type of products intended for oncologic
indications suggest that the Regulation also provides
support for the development of the more classical antican-
cer drugs. In fact, this is one of the most successful niches
in orphan drug development in the EU so far.
Recent literature has discussed factors that influenced the
development of orphan medicinal products in Europe [12,
14, 19]. One of the issues that has been raised in these
papers is the absence of tax credits in the EU, compared to
the USA. The reason for this is that taxation is still a
national affair in the EU, which is not regulated at the
Community level. Although this is compensated for by a
longer period of market exclusivity in the EU and
additional benefits on a national level [20], Joppi and Dear
suggest that this may yield fewer orphan drugs than in the
USA [12, 14]. While our analysis cannot fully produce a
conclusive answer to this discussion, it gives some useful
clues that the absence of tax credits alone is not the reason
for the lower number of approved products in the EU.
Approximately one-third of the European orphan desig-
nations were originally developed in the USA (data on file).
However, in our analysis, no association was found
between the continent of drug development and market
authorisation. These results suggest that the absence of tax
credits in the EU does not discourage companies from
applying for an orphan designation in the EU.
Wästfelt described the problems of performing adequate-
ly powered RCTs in small patient populations with rare
diseases, which are even more problematic in the multicul-
tural and multilingual setting of the EU compared to the
USA [5]. Moreover, the USA has a successful infrastructure
for conducting trials in patient populations with rare
diseases, which is coordinated by the Rare Diseases
Clinical Research Network and supported by the Office of
Rare Diseases of the National Institutes of Health [5]. If the
small patient populations were really the key problem, we
would see a larger share of orphan drugs for relatively
common rare diseases in the EU, and only a very small
share of orphan drugs indicated for the very rare diseases.
However, in our analysis, we found no association between
prevalence of the indication and market authorisation.
Moreover, of the 36 indications for which an orphan
medicinal product has been approved in the EU, 24 (67%)
had a prevalence of less than 1 per 10,000. In addition to
this, Dear stated that, although small patient numbers may
hamper clinical trials for very rare diseases, it is not likely
to be a problem for more prevalent rare diseases [12].
We need to consider other critical factors for the success
of the development of an orphan drug. The level of patient
involvement may also influence successful development
and subsequent authorisation of orphan drugs [5]. More-
over, the registration dossiers of authorised orphan drugs
are often of poor quality, including inappropriate study
design, lack of active comparators and inadequate end-
points [14, 19]. Although this criticism is primarily directed
against orphan drugs already authorised, it is very possible
that these dossiers are just the ‘tip of the iceberg’. If that is
the case, many orphan drugs will not reach the market
because the sponsor will not be able to show evidence of
favourable characteristics of the product due to the poor
quality of the dossier. Since this study has been based on
data from the public domain, several of these factors could
not be included, which is a limitation of the study. Future
research to investigate the quality of the clinical develop-
ment program of designated (unauthorised) orphan drugs
is needed.
Another possible limitation of the study was the risk of
biased outcomes due to possible differences in the stage of
development of the products between the two groups that
were compared. For this reason, the controls were randomly
sampled from the same calendar period as the cases, so that
the chance that products would obtain approval was as
equal as possible. Moreover, we compared the stage of
development at the time of the application for orphan
designation based on data from the available Summaries of
Opinion of the EMEA. Here it was shown that, although
slight differences existed, the two groups were roughly
equal with regard to their stage of development at time of
orphan designation.
The relatively small number of products that have so far
been approved in the EU as compared to the enormous
number of rare diseases emphasises that the promises of the
European Regulation on OMPs have yet to be fulfilled.
This paper has studied the characteristics of several of the
early approved orphan drugs, the majority of them
authorised within the first 2 years of the Regulation. Now
that the Regulation is about to enter its ninth year of
existence, the rate of orphan drug approval is gradually
Eur J Clin Pharmacol (2008) 64:545–552 551
increasing and more and more orphan drugs are entering
the market for the seriously needed treatment of patients
with rare diseases.
In conclusion, we have found that experience in the drug
development process and development of already existing
(small) molecules are associated with market authorisation
of orphan drug designations. The EMEA addresses this
with several helpful incentives to support inexperienced
companies in their orphan drug development. There seems
to be a steep learning curve for inexperienced companies.
The incentives forthcoming from the European Regulation
on Orphan Medicinal Products seem to be helpful for
companies developing orphan drugs, although the industry
has to ‘grow’ and acquire expertise on the specific
peculiarities of the orphan drug development process. The
differences in orphan drug approvals between the EU and
the USA may therefore be best explained by the maturity of
the US pharmaceutical and biotech industry compared to
Europe. In addition to this factor, other characteristics
related to the quality, safety and efficacy profile of a
potential orphan drug certainly play a role. Especially with
regard to the possibilities of sponsors to demonstrate
clinical evidence of the orphan drug under development.
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